This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Iversen, A. K.
Right arrow Articles by Merigan, T. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Iversen, A. K.
Right arrow Articles by Merigan, T. C.

 Previous Article  |  Next Article 

J. Virol., 02 1996, 1086-1090, Vol 70, No. 2
Copyright © 1996, American Society for Microbiology

Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy

AK Iversen, RW Shafer, K Wehrly, MA Winters, JI Mullins, B Chesebro and TC Merigan
Division of Infectious Diseases and Geographic Medicine, Stanford University, California 94305, USA.

Multidrug-resistant human immunodeficiency virus type 1 (HIV-1) strains with reverse transcriptase (RT) mutations at codons A62-->V, V75-->I, F77-->L, F116-->Y, and Q151-->M have been reported in patients receiving combination therapy with zidovudine (AZT) and didanosine (ddI). Infectious clones with each mutation alone, all five mutations together, and various combinations of mutations were created by site- directed mutagenesis. Mutation Q151-->M conferred partial resistance to AZT, ddI, zalcitibine, and stavudine, whereas a combination of four mutations conferred increased resistance to AZT, ddI, zalcitibine, and stavudine. The positions of residues 75, 77, and 151 in the three- dimensional crystal structure of HIV-1 RT suggest that these residues may affect the ability of the enzyme to discriminate between deoxynucleoside triphosphates and nucleoside analog RT inhibitors. Replication experiments showed that clones with mutation F77-->L but without V75-->I (HIV-1(77), HIV-1(77,151), and HIV-1(77,116,151) had attenuated growth compared with that of the original HIV-1NL4-3 strain and strains containing mutations at both positions 75 and 77 (HIV- 1(75,77,151) and HIV-1(75,77,116,15)). Sequence analysis of viral RNA and proviral DNA from several patients indicated that RT mutations developed in a sequential and cumulative pattern over the course of a 2- to 4-year observation period. The present results suggest that drug resistance and viral replicative capacity both may play a role in selection of HIV-1 RT mutations.


This article has been cited by other articles:

  • Matamoros, T., Nevot, M., Martinez, M. A., Menendez-Arias, L. (2009). Thymidine Analogue Resistance Suppression by V75I of HIV-1 Reverse Transcriptase: EFFECTS OF SUBSTITUTING VALINE 75 ON STAVUDINE EXCISION AND DISCRIMINATION. J. Biol. Chem. 284: 32792-32802 [Abstract] [Full Text]  
  • Waleria-Aleixo, A., Martins, A. N., Arruda, M. B., Brindeiro, R. M., Da-Silva, R. M., Nobre, F. F., Greco, D. B., Tanuri, A. (2008). Drug Resistance Mutation Profile and Accumulation Kinetics in Human Immunodeficiency Virus-Positive Individuals Infected with Subtypes B and F Failing Highly Active Antiretroviral Therapy Are Influenced by Different Viral Codon Usage Patterns. Antimicrob. Agents Chemother. 52: 4497-4502 [Abstract] [Full Text]  
  • Smith, R. A., Gottlieb, G. S., Anderson, D. J., Pyrak, C. L., Preston, B. D. (2008). Human Immunodeficiency Virus Types 1 and 2 Exhibit Comparable Sensitivities to Zidovudine and Other Nucleoside Analog Inhibitors In Vitro. Antimicrob. Agents Chemother. 52: 329-332 [Abstract] [Full Text]  
  • Karlsson, A. C., Chapman, J. M., Heiken, B. D., Hoh, R., Kallas, E. G., Martin, J. N., Hecht, F. M., Deeks, S. G., Nixon, D. F. (2007). Antiretroviral Drug Therapy Alters the Profile of Human Immunodeficiency Virus Type 1-Specific T-Cell Responses and Shifts the Immunodominant Cytotoxic T-Lymphocyte Response from Gag to Pol. J. Virol. 81: 11543-11548 [Abstract] [Full Text]  
  • Saigo, H., Uno, T., Tsuda, K. (2007). Mining complex genotypic features for predicting HIV-1 drug resistance. Bioinformatics 23: 2455-2462 [Abstract] [Full Text]  
  • Villena, C., Prado, J. G., Puertas, M. C., Martinez, M. A., Clotet, B., Ruiz, L., Parkin, N. T., Menendez-Arias, L., Martinez-Picado, J. (2007). Relative Fitness and Replication Capacity of a Multinucleoside Analogue-Resistant Clinical Human Immunodeficiency Virus Type 1 Isolate with a Deletion of Codon 69 in the Reverse Transcriptase Coding Region. J. Virol. 81: 4713-4721 [Abstract] [Full Text]  
  • Jochmans, D., Deval, J., Kesteleyn, B., Van Marck, H., Bettens, E., De Baere, I., Dehertogh, P., Ivens, T., Van Ginderen, M., Van Schoubroeck, B., Ehteshami, M., Wigerinck, P., Gotte, M., Hertogs, K. (2006). Indolopyridones Inhibit Human Immunodeficiency Virus Reverse Transcriptase with a Novel Mechanism of Action. J. Virol. 80: 12283-12292 [Abstract] [Full Text]  
  • Smith, R. A., Anderson, D. J., Preston, B. D. (2006). Hypersusceptibility to Substrate Analogs Conferred by Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase. J. Virol. 80: 7169-7178 [Abstract] [Full Text]  
  • Gonzalez, L. M. F., Aguiar, R. S., Afonso, A., Brindeiro, P. A., Arruda, M. B., Soares, M. A., Brindeiro, R. M., Tanuri, A. (2006). Biological characterization of human immunodeficiency virus type 1 subtype C protease carrying indinavir drug-resistance mutations.. J. Gen. Virol. 87: 1303-1309 [Abstract] [Full Text]  
  • van der Hoek, L., Back, N., Jebbink, M. F., de Ronde, A., Bakker, M., Jurriaans, S., Reiss, P., Parkin, N., Berkhout, B. (2005). Increased Multinucleoside Drug Resistance and Decreased Replicative Capacity of a Human Immunodeficiency Virus Type 1 Variant with an 8-Amino-Acid Insert in the Reverse Transcriptase. J. Virol. 79: 3536-3543 [Abstract] [Full Text]  
  • Rhodes, T. D., Nikolaitchik, O., Chen, J., Powell, D., Hu, W.-S. (2005). Genetic Recombination of Human Immunodeficiency Virus Type 1 in One Round of Viral Replication: Effects of Genetic Distance, Target Cells, Accessory Genes, and Lack of High Negative Interference in Crossover Events. J. Virol. 79: 1666-1677 [Abstract] [Full Text]  
  • Paolucci, S., Baldanti, F., Maga, G., Cancio, R., Zazzi, M., Zavattoni, M., Chiesa, A., Spadari, S., Gerna, G. (2004). Gln145Met/Leu Changes in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Resistance to Nucleoside and Nonnucleoside Analogs and Impair Virus Replication. Antimicrob. Agents Chemother. 48: 4611-4617 [Abstract] [Full Text]  
  • Tamiya, S., Mardy, S., Kavlick, M. F., Yoshimura, K., Mistuya, H. (2004). Amino Acid Insertions near Gag Cleavage Sites Restore the Otherwise Compromised Replication of Human Immunodeficiency Virus Type 1 Variants Resistant to Protease Inhibitors. J. Virol. 78: 12030-12040 [Abstract] [Full Text]  
  • Smith, R. A., Anderson, D. J., Preston, B. D. (2004). Purifying Selection Masks the Mutational Flexibility of HIV-1 Reverse Transcriptase. J. Biol. Chem. 279: 26726-26734 [Abstract] [Full Text]  
  • Matamoros, T., Franco, S., Vazquez-Alvarez, B. M., Mas, A., Martinez, M. A., Menendez-Arias, L. (2004). Molecular Determinants of Multi-nucleoside Analogue Resistance in HIV-1 Reverse Transcriptases Containing a Dipeptide Insertion in the Fingers Subdomain: EFFECT OF MUTATIONS D67N AND T215Y ON REMOVAL OF THYMIDINE NUCLEOTIDE ANALOGUES FROM BLOCKED DNA PRIMERS. J. Biol. Chem. 279: 24569-24577 [Abstract] [Full Text]  
  • Paolucci, S., Baldanti, F., Zavattoni, M., Gerna, G. (2004). Novel recombinant phenotypic assay for clonal analysis of reverse transcriptase mutations conferring drug resistance to HIV-1 variants. J Antimicrob Chemother 53: 766-771 [Abstract] [Full Text]  
  • Clavel, F., Hance, A. J. (2004). HIV Drug Resistance. NEJM 350: 1023-1035 [Full Text]  
  • Turner, D., Brenner, B., Wainberg, M. A. (2004). Relationships among various nucleoside resistance-conferring mutations in the reverse transcriptase of HIV-1. J Antimicrob Chemother 53: 53-57 [Abstract] [Full Text]  
  • Delaney, W. E. IV, Yang, H., Westland, C. E., Das, K., Arnold, E., Gibbs, C. S., Miller, M. D., Xiong, S. (2003). The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In Vitro. J. Virol. 77: 11833-11841 [Abstract] [Full Text]  
  • Blanca, G., Baldanti, F., Paolucci, S., Skoblov, A. Y., Victorova, L., Hubscher, U., Gerna, G., Spadari, S., Maga, G. (2003). Nevirapine Resistance Mutation at Codon 181 of the HIV-1 Reverse Transcriptase Confers Stavudine Resistance by Increasing Nucleotide Substrate Discrimination and Phosphorolytic Activity. J. Biol. Chem. 278: 15469-15472 [Abstract] [Full Text]  
  • Sturmer, M., Staszewski, S., Doerr, H.-W., Larder, B., Bloor, S., Hertogs, K. (2003). Correlation of Phenotypic Zidovudine Resistance with Mutational Patterns in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1: Interpretation of Established Mutations and Characterization of New Polymorphisms at Codons 208, 211, and 214. Antimicrob. Agents Chemother. 47: 54-61 [Abstract] [Full Text]  
  • Deval, J., Selmi, B., Boretto, J., Egloff, M. P., Guerreiro, C., Sarfati, S., Canard, B. (2002). The Molecular Mechanism of Multidrug Resistance by the Q151M Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Its Suppression Using alpha -Boranophosphate Nucleotide Analogues. J. Biol. Chem. 277: 42097-42104 [Abstract] [Full Text]  
  • Aslanzadeh, J. (2002). HIV Resistance Testing: an Update. Annals of Clinical & Laboratory Science 32: 406-413 [Abstract] [Full Text]  
  • Montes, B., Segondy, M. (2002). Amino Acid Substitutions at Position 69 of the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 Are Frequent in Zalcitabine-Naive Antiretroviral-Drug-Experienced Patients. Antimicrob. Agents Chemother. 46: 3110-3111 [Full Text]  
  • Shafer, R. W. (2002). Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance. Clin. Microbiol. Rev. 15: 247-277 [Abstract] [Full Text]  
  • Masquelier, B., Race, E., Tamalet, C., Descamps, D., Izopet, J., Buffet-Janvresse, C., Ruffault, A., Mohammed, A. S., Cottalorda, J., Schmuck, A., Calvez, V., Dam, E., Fleury, H., Brun-Vézinet, F., the ANRS AC11 Resistance Study Group, (2001). Genotypic and Phenotypic Resistance Patterns of Human Immunodeficiency Virus Type 1 Variants with Insertions or Deletions in the Reverse Transcriptase (RT): Multicenter Study of Patients Treated with RT Inhibitors. Antimicrob. Agents Chemother. 45: 1836-1842 [Abstract] [Full Text]  
  • Delaugerre, C., Mouroux, M., Yvon-Groussin, A., Simon, A., Angleraud, F., Huraux, J.-M., Agut, H., Katlama, C., Calvez, V. (2001). Prevalence and Conditions of Selection of E44D/A and V118I Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutations in Clinical Practice. Antimicrob. Agents Chemother. 45: 946-948 [Abstract] [Full Text]  
  • Imamichi, T., Berg, S. C., Imamichi, H., Lopez, J. C., Metcalf, J. A., Falloon, J., Lane, H. C. (2000). Relative Replication Fitness of a High-Level 3'-Azido-3'-Deoxythymidine-Resistant Variant of Human Immunodeficiency Virus Type 1 Possessing an Amino Acid Deletion at Codon 67 and a Novel Substitution (Thrright-arrowGly) at Codon 69. J. Virol. 74: 10958-10964 [Abstract] [Full Text]  
  • Halvas, E. K., Svarovskaia, E. S., Pathak, V. K. (2000). Role of Murine Leukemia Virus Reverse Transcriptase Deoxyribonucleoside Triphosphate-Binding Site in Retroviral Replication and In Vivo Fidelity. J. Virol. 74: 10349-10358 [Abstract] [Full Text]  
  • García-Lerma, J. G., Gerrish, P. J., Wright, A. C., Qari, S. H., Heneine, W. (2000). Evidence of a Role for the Q151L Mutation and the Viral Background in Development of Multiple Dideoxynucleoside-Resistant Human Immunodeficiency Virus Type 1. J. Virol. 74: 9339-9346 [Abstract] [Full Text]  
  • Van Vaerenbergh, K., Van Laethem, K., Albert, J., Boucher, C. A. B., Clotet, B., Floridia, M., Gerstoft, J., Hejdeman, B., Nielsen, C., Pannecouque, C., Perrin, L., Pirillo, M. F., Ruiz, L., Schmit, J.-C., Schneider, F., Schoolmeester, A., Schuurman, R., Stellbrink, H. J., Stuyver, L., Van Lunzen, J., Van Remoortel, B., Van Wijngaerden, E., Vella, S., Witvrouw, M., Yerly, S., De Clercq, E., Desmyter, J., Vandamme, A.-M. (2000). Prevalence and Characteristics of Multinucleoside-Resistant Human Immunodeficiency Virus Type 1 among European Patients Receiving Combinations of Nucleoside Analogues. Antimicrob. Agents Chemother. 44: 2109-2117 [Abstract] [Full Text]  
  • Bonfanti, P., Faggion, I., Catamancio, S. L. S., Violin, M., Balotta, C., Rusconi, S. (2000). Response to Antiretroviral Therapy in a Patient with an Uncommon Codon 69 Insertion in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase. Antimicrob. Agents Chemother. 44: 1767-1768 [Full Text]  
  • Rusconi, S., La Seta Catamancio, S., Citterio, P., Kurtagic, S., Violin, M., Balotta, C., Moroni, M., Galli, M., d'Arminio-Monforte, A. (2000). Susceptibility to PNU-140690 (Tipranavir) of Human Immunodeficiency Virus Type 1 Isolates Derived from Patients with Multidrug Resistance to Other Protease Inhibitors. Antimicrob. Agents Chemother. 44: 1328-1332 [Abstract] [Full Text]  
  • Petropoulos, C. J., Parkin, N. T., Limoli, K. L., Lie, Y. S., Wrin, T., Huang, W., Tian, H., Smith, D., Winslow, G. A., Capon, D. J., Whitcomb, J. M. (2000). A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1. Antimicrob. Agents Chemother. 44: 920-928 [Abstract] [Full Text]  
  • Endy, D., Yin, J. (2000). Toward Antiviral Strategies That Resist Viral Escape. Antimicrob. Agents Chemother. 44: 1097-1099 [Abstract] [Full Text]  
  • Hertogs, K., Bloor, S., De Vroey, V., van den Eynde, C., Dehertogh, P., van Cauwenberge, A., Stürmer, M., Alcorn, T., Wegner, S., van Houtte, M., Miller, V., Larder, B. A. (2000). A Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutational Pattern Confers Phenotypic Lamivudine Resistance in the Absence of Mutation 184V. Antimicrob. Agents Chemother. 44: 568-573 [Abstract] [Full Text]  
  • Larder, B. A., Bloor, S., Kemp, S. D., Hertogs, K., Desmet, R. L., Miller, V., Sturmer, M., Staszewski, S., Ren, J., Stammers, D. K., Stuart, D. I., Pauwels, R. (1999). A Family of Insertion Mutations between Codons 67 and 70 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Multinucleoside Analog Resistance. Antimicrob. Agents Chemother. 43: 1961-1967 [Abstract] [Full Text]  
  • Palmer, S., Shafer, R. W., Merigan, T. C. (1999). Hydroxyurea Enhances the Activities of Didanosine, 9-[2-(Phosphonylmethoxy)ethyl]adenine, and 9-[2-(Phosphonylmethoxy)propyl]adenine against Drug-Susceptible and Drug-Resistant Human Immunodeficiency Virus Isolates. Antimicrob. Agents Chemother. 43: 2046-2050 [Abstract] [Full Text]  
  • Smith, R. A., Klarmann, G. J., Stray, K. M., von Schwedler, U. K., Schinazi, R. F., Preston, B. D., North, T. W. (1999). A New Point Mutation (P157S) in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 Confers Low-Level Resistance to (-)-beta -2',3'-Dideoxy-3'-Thiacytidine. Antimicrob. Agents Chemother. 43: 2077-2080 [Abstract] [Full Text]  
  • Olivares, I., Sánchez-Merino, V., Martínez, M. A., Domingo, E., López-Galíndez, C., Menéndez-Arias, L. (1999). Second-Site Reversion of a Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutant That Restores Enzyme Function and Replication Capacity. J. Virol. 73: 6293-6298 [Abstract] [Full Text]  
  • Kosalaraksa, P., Kavlick, M. F., Maroun, V., Le, R., Mitsuya, H. (1999). Comparative Fitness of Multi-Dideoxynucleoside-Resistant Human Immunodeficiency Virus Type 1 (HIV-1) in an In Vitro Competitive HIV-1 Replication Assay. J. Virol. 73: 5356-5363 [Abstract] [Full Text]  
  • Gerondelis, P., Archer, R. H., Palaniappan, C., Reichman, R. C., Fay, P. J., Bambara, R. A., Demeter, L. M. (1999). The P236L Delavirdine-Resistant Human Immunodeficiency Virus Type 1 Mutant Is Replication Defective and Demonstrates Alterations in both RNA 5'-End- and DNA 3'-End-Directed RNase H Activities. J. Virol. 73: 5803-5813 [Abstract] [Full Text]  
  • Wainberg, M. A. (1999). A New Source of Resistance to HIV Drugs. JAMA 281: 2169-2170 [Full Text]  
  • García Lerma, J. G., Schinazi, R. F., Juodawlkis, A. S., Soriano, V., Lin, Y., Tatti, K., Rimland, D., Folks, T. M., Heneine, W. (1999). A Rapid Non-Culture-Based Assay for Clinical Monitoring of Phenotypic Resistance of Human Immunodeficiency Virus Type 1 to Lamivudine (3TC). Antimicrob. Agents Chemother. 43: 264-270 [Abstract] [Full Text]  
  • Tachedjian, G., French, M., Mills, J. (1998). Coresistance to Zidovudine and Foscarnet Is Associated with Multiple Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase. Antimicrob. Agents Chemother. 42: 3038-3043 [Abstract] [Full Text]  
  • Arts, E. J., Quinones-Mateu, M. E., Albright, J. L., Marois, J.-P., Hough, C., Gu, Z., Wainberg, M. A. (1998). 3'-Azido-3'-Deoxythymidine (AZT) Mediates Cross-Resistance to Nucleoside Analogs in the Case of AZT-Resistant Human Immunodeficiency Virus Type 1 Variants. J. Virol. 72: 4858-4865 [Abstract] [Full Text]  
  • Rezende, L. F., Curr, K., Ueno, T., Mitsuya, H., Prasad, V. R. (1998). The Impact of Multidideoxynucleoside Resistance-Conferring Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase on Polymerase Fidelity and Error Specificity. J. Virol. 72: 2890-2895 [Abstract] [Full Text]  
  • Smith, R. A., Remington, K. M., Preston, B. D., Schinazi, R. F., North, T. W. (1998). A Novel Point Mutation at Position 156 of Reverse Transcriptase from Feline Immunodeficiency Virus Confers Resistance to the Combination of (-)-beta -2',3'-Dideoxy-3'-Thiacytidine and 3'-Azido-3'-Deoxythymidine. J. Virol. 72: 2335-2340 [Abstract] [Full Text]  
  • Hertogs, K., de Béthune, M.-P., Miller, V., Ivens, T., Schel, P., Van Cauwenberge, A., Van den Eynde, C., van Gerwen, V., Azijn, H., van Houtte, M., Peeters, F., Staszewski, S., Conant, M., Bloor, S., Kemp, S., Larder, B., Pauwels, R. (1998). A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs. Antimicrob. Agents Chemother. 42: 269-276 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»